Earlier studies with a monoclonal antibody report a generally lower prevalence of Survivin expression in 34% of gastric carcinomas (Lu et al, 1998), 53–61% of colorectal carcinomas (Kawasaki et al, 1998; Sarela et al, 2001), and 71% of breast carcinomas (Tanaka et al, 2000). Here, BIRC5 is linked to colorectal carcinoma.